Only through Arjil, better life could be true.
One Arjil product a day keeps the Day great!
Focus on the development of small molecule drugs.
Bringing a healthy future to people, A better life begins with ARJIL.
ARJIL Pharmaceuticals LLC, founded in 2014, is a clinical-stage biopharmaceutical company pioneering innovative therapies. Our pipeline focuses on botanical-based medicines and promising small molecule drug candidates, aiming to improve the health and well-being of aging individuals. As of 2024, Arjil‘s funding investment has exceeded 8 million US Dollars.
Service
Research and Development
We are committed to developing medicines for unmet medical needs and improving quality life products, including bioactive botanical cosmetic ingredients, healthy foods derived from botanical drugs, and anti-aging products for improving and extending quality of life for elderly people.
Research
ARJIL Strength
Dr. Yeh B, Wu Chairman
With the QMS (Quality Management System) having been established on our organization infrastructure along the IND process, we have been holistically approaching and accelerating our drug R&D in data driven & risk managed (assessed) manners, and consistently moving toward a successful track in a predictable way.
After practicing medicine in US for 40 years, transitioned into the pharmaceutical industry upon retirement.
New York University Bellevue Hospital , NY
Setup anesthesia and pain clinic, NJ
Zeitech Corp Chairman, NJ
Investment in Arch Venture Fund, Chicago
Zeitech Corp Chairman, NJ
TBS Pharmaceutical Company Board of Directors, NJ
Barjil Investment Group Chairman, NJ
Dr. James Sheu
Chief Science Officer
Ph.D., Department of Chemistry, University of Connecticut
Head of Medicines Division at the Biomedical Technology and Device Research Laboratories, ITRI
Director of the Material and Chemical Research Laboratories, ITRI
Richard Wu
MD
medical adviser Emergency Care and Thoracic Specialty Columbia University
Dr. Jane SC Tsai
Honorary Consultant U.S.A. SVP(Senior Vice President) International Affairs, YFY Biotech Management CompanySenior Advisor, Former Deputy General Director and COO(Chief Operating Officer), CTO(Chief Technology Officer), ITRI Roche Former Director,
Julian Yu
Chief Financial Officer
BS. EMBA , Department of Finance, National Taiwan University Director, Audit Division, Financial Department, Council of Economic Planning and Development Director, Risk Management Department, Laber Pension Fund Supersivise Committee Director, Domestic Investment Management Department, Bureau of Laber Pension Fund
Dr. Ming-Kun Chen
Manager
Postdoc. National Chung Hsing University PhD, Biotechnology, NCHU
Hui-Ju Liang
Product Manager
Biomedical Technology and Device Research Laboratories, ITRI Natural product isolation NTOU, Master